Hypoglycemia on a GLP-1: Who Is Actually at Risk, and What the Warning Signs Look Like

On their own, only rarely. The reason lies in how these drugs work, and it is one of the more elegant features of the drug class.

Hypoglycemia means a blood glucose level low enough to cause symptoms, conventionally below 70 mg/dL (3.9 mmol/L). It happens when there is more insulin circulating than the available glucose requires. Older diabetes drugs such as sulfonylureas force the pancreas to release insulin regardless of what your glucose is doing, which is exactly why they cause lows.

GLP-1 receptor agonists work differently. They amplify insulin release in a glucose-dependent way: the signal only fires when glucose is already elevated. As glucose falls back toward normal, the insulin-stimulating effect switches off. They also suppress glucagon, the hormone that raises glucose, but again only when glucose is high. That built-in off-switch is why the risk profile is so different. Our explainer on [how GLP-1 medications actually work](/blog/how-glp1-medications-work-mechanism-explained) walks through the mechanism in full.

The trial data reflect this. In SUSTAIN-1, where semaglutide was used as monotherapy in people with type 2 diabetes, severe or blood-glucose-confirmed symptomatic hypoglycemia occurred in under 1% of participants across both dose arms, with rates comparable to placebo (Sorli et al., Lancet Diabetes & Endocrinology, 2017). In the STEP 1 obesity trial, where participants did not have diabetes, hypoglycemia was not a meaningful safety signal (Wilding et al., NEJM 2021).

So if you are taking a GLP-1 alone for weight management, the odds that your shaky, sweaty feeling is genuine hypoglycemia are low. That does not mean the feeling is imaginary. It usually means something else is causing it, which is worth identifying rather than dismissing.

The risk is concentrated in a few specific groups, and if you are not in one of them your baseline risk is low.

People taking a sulfonylurea. This is the largest risk group by a wide margin. Sulfonylureas include glipizide, glimepiride, glyburide and gliclazide. They push insulin out regardless of glucose level. Add a GLP-1 that also lowers glucose and you can stack two effects on top of each other. Clinical guidance is consistent here: the American Diabetes Association Standards of Care advise reducing or stopping the sulfonylurea when a GLP-1 is added, precisely to prevent this.

People taking insulin. Same logic, more precision required. Basal insulin doses are commonly reduced by around 20% when a GLP-1 is introduced, though the exact adjustment depends on your current control and should always come from your prescriber, not from an article.

People who are eating dramatically less than they used to. This is the group that surprises people. A GLP-1 can cut intake by half within weeks. If your diabetes medication doses were set for your old eating pattern, they may now be too strong for your new one. Doses that were correct in month one can become excessive by month three.

People with a history of bariatric surgery. Post-bariatric hypoglycemia is a recognised entity involving an exaggerated insulin response after meals. Adding a GLP-1 to that picture warrants closer monitoring.

People with kidney or liver impairment, in whom medications clear more slowly and glucose regulation is less robust.

If you have PCOS and are using a GLP-1, insulin dynamics are already part of your picture; our guide to [GLP-1 medications for PCOS](/blog/glp1-medications-for-pcos-what-the-research-shows) covers what the research shows.

Hypoglycemia symptoms arrive in two waves, and knowing the order helps you catch it early.

The first wave is adrenergic, driven by the adrenaline your body releases to push glucose back up. These typically appear around 70 mg/dL (3.9 mmol/L):

• •Shakiness or trembling
• •Sweating, often cold and clammy
• •A racing or pounding heartbeat
• •Sudden intense hunger
• •Anxiety or an unexplained sense of dread
• •Tingling around the lips

The second wave is neuroglycopenic, meaning the brain itself is short of fuel. These appear lower, usually below 55 mg/dL (3.0 mmol/L), and are more serious:

• •Confusion or difficulty concentrating
• •Slurred speech
• •Blurred or double vision
• •Poor coordination, stumbling
• •Irritability or personality change
• •In severe cases, seizure or loss of consciousness

Two complications are worth knowing about. The first is hypoglycemia unawareness, where repeated lows blunt the adrenergic warning wave, so the first symptom you notice is confusion. This is more common in people who have had diabetes for many years.

The second is more relevant to most readers: the adrenergic symptom list overlaps almost completely with dehydration, low sodium, anxiety and simple under-eating, all of which are common on a GLP-1. Palpitations and a sense of dread are also core menopause symptoms, as covered in [menopause heart palpitations](/blog/menopause-heart-palpitations-why-your-heart-races-and-what-helps). Feeling shaky is not a diagnosis. It is a prompt to check.

With a meter or a continuous glucose monitor. There is no reliable way to do it by feel, and this is the single most useful thing to take from this article.

If you do not take insulin or a sulfonylurea, the odds strongly favour a non-glucose explanation. Three impostors account for most cases.

Dehydration and low sodium. GLP-1s blunt thirst alongside appetite. Reduced fluid intake plus reduced food-borne sodium produces lightheadedness, weakness, palpitations and a head rush on standing, all of which read as hypoglycemia. This is common enough that we cover it separately in [dizziness and lightheadedness on a GLP-1](/blog/glp1-dizziness-lightheadedness-causes-and-fixes).

Genuine under-eating. Not hypoglycemia, but not nothing either. If nausea has kept you at 700 calories for three days, you will feel weak, shaky and cognitively slow with entirely normal blood glucose. Your body is running on fumes without your glucose ever dropping below range. The fix is food, not glucose tablets. Our [injection day meal guide](/blog/what-to-eat-on-glp1-injection-day-meal-guide) is built for exactly these low-appetite days.

Anxiety. Adrenaline produces the same symptom cluster from the other direction, and a bad hypo experience can start a feedback loop where the fear itself generates the symptoms.

A useful diagnostic habit is Whipple's triad, the standard clinical test for whether hypoglycemia is real: symptoms are present, a measured glucose is genuinely low, and the symptoms resolve when glucose is corrected. All three, not one. If you check and your glucose is 95 mg/dL, you have just learned something valuable, and you have saved yourself from treating a non-low with sugar you did not need.

If you are already using a CGM, our guide to [what glucose data actually shows on a GLP-1](/blog/cgm-on-glp1-during-menopause-what-glucose-data-shows) covers how to read the traces without over-interpreting normal variability.

The standard response is the 15-15 rule, and it is worth committing to memory before you need it.

If glucose is below 70 mg/dL (3.9 mmol/L) and you are conscious and able to swallow:

1. Take 15 grams of fast-acting carbohydrate. Four glucose tablets, 120 ml of regular fruit juice, 150 ml of non-diet soft drink, or a tablespoon of honey. 2. Wait 15 minutes. This is the part people skip. Eating more because you do not feel better yet is the most common cause of a rebound high. 3. Recheck. If still below 70 mg/dL, repeat the 15 grams. 4. Once back in range, eat a small snack containing protein and complex carbohydrate if your next meal is more than an hour away.

A GLP-1-specific complication: these medications slow gastric emptying, so solid or fatty carbohydrates are absorbed more slowly than they would be otherwise. Liquid glucose is the better choice here. Chocolate is a poor rescue food generally, and worse on a GLP-1, because its fat content further delays absorption.

For severe hypoglycemia, where the person is confused, unable to swallow safely, or unconscious: do not put anything in their mouth. Use glucagon if it has been prescribed, whether the injectable kit or the nasal spray, and call emergency services. Anyone taking insulin or a sulfonylurea alongside a GLP-1 should have glucagon available and at least one household member who knows where it is.

Afterwards, treat any confirmed low as information rather than an isolated event. One low means your regimen needs a look. Two or more means it needs a change, which may mean adjusting the sulfonylurea or insulin rather than the GLP-1 itself. Our guide to [dose escalation and when to hold](/blog/glp1-dose-escalation-when-to-increase-and-when-to-hold) is useful context for that conversation.

Monitoring should match your actual risk rather than your anxiety level.

If you take a GLP-1 alone with no diabetes, routine glucose monitoring is not usually required. Owning an inexpensive meter is still reasonable for peace of mind, so that when you feel off you can settle the question in sixty seconds instead of worrying about it all day.

If you take a sulfonylurea or insulin, monitoring is not optional, especially during the first eight to twelve weeks and around every dose increase. Check before driving. A CGM is genuinely valuable here because it shows the overnight lows that fingersticks miss entirely.

If you have had bariatric surgery, a CGM is worth requesting, as post-meal patterns are the specific thing you need to see.

Questions worth bringing to your appointment:

• •Should my sulfonylurea or insulin dose change now that I am starting a GLP-1?
• •What is my personal target range, and at what number should I act?
• •Do I need a glucagon prescription, and who at home should be shown how to use it?
• •How often should my HbA1c be rechecked while I am losing weight?
• •If I am eating substantially less than I was, does my whole regimen need revisiting rather than just one drug?

That last question is the one that gets missed most often. Weight loss on a GLP-1 improves insulin sensitivity over months, meaning the diabetes medications that were correctly dosed at the start can gradually become too strong. Hypoglycemia appearing at month four in someone who had none at month one is usually a sign of success that needs a dose reduction, not a new problem. Bring your readings to the appointment; a pattern is far more useful to your clinician than a description.